310 related articles for article (PubMed ID: 35771021)
1. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
[TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III.
Alanezi M; Yan AT; Tan MK; Bourgeois R; Malek-Marzban P; Beharry R; Alkurtass S; Gyenes GT; Nadeau PL; Nwadiaro N; Jedrzkiewicz S; Gao D; Chandna H; Nelson WB; Goodman SG;
Cardiology; 2024; 149(3):266-274. PubMed ID: 38290490
[TBL] [Abstract][Full Text] [Related]
5. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
Hao Y; Yang YL; Wang YC; Li J
Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
[TBL] [Abstract][Full Text] [Related]
6. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
7. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
[TBL] [Abstract][Full Text] [Related]
8. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
[TBL] [Abstract][Full Text] [Related]
9. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
[TBL] [Abstract][Full Text] [Related]
10. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
[TBL] [Abstract][Full Text] [Related]
11. Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.
Nguy J; Hitchen SA; Lan NSR; Dwivedi G; Larbalestier R; Yeap BB; Fegan PG
Intern Med J; 2023 Jun; 53(6):994-1001. PubMed ID: 35112773
[TBL] [Abstract][Full Text] [Related]
12. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
[TBL] [Abstract][Full Text] [Related]
13. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
14. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
15. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
16. Guideline-Directed Low-Density Lipoprotein Cholesterol Management After Acute Ischemic Stroke: Findings from a National Health Care Service.
Zafrir B; Aker A; Naoum I; Saliba W
Am J Cardiol; 2023 Sep; 203():332-338. PubMed ID: 37517128
[TBL] [Abstract][Full Text] [Related]
17. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
18. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
Liu Y; Han B
Transpl Immunol; 2022 Apr; 71():101444. PubMed ID: 34375677
[TBL] [Abstract][Full Text] [Related]
19. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
[TBL] [Abstract][Full Text] [Related]
20. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
[No Abstract] [Full Text] [Related]
[Next] [New Search]